Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis

NCT03560557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2021-01-22

No results posted yet for this study

Summary

WP1.1. PK/PD target attainment: Plasma exposure, Excretion via urine \& ELF exposure; WP1.2. Predictive dosing algorithm; WP1.3. ECMO subset

Conditions

  • Critical Illness
  • Pharmacokinetics

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Isabel Spriet, PharmD PhD · UZ Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03560557 on ClinicalTrials.gov